Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII-SingleChain and other common rFVIII products in Germany.

Among these products, factor consumption was lowest in patients using rVIII‐SingleChain in all patients as well as in those specifically with severe disease, although the comparison in patients with severe disease did not reach statistical significance likely due to the small sample sizes as a major factor.

also in 111,027 other papers